Cutting sugar may not significantly impact hair loss, as DHT and androgenreceptors are the main issues. Effective treatments include finasteride, dutasteride, RU58841, and minoxidil, often combined with microneedling.
GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgenreceptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.
The conversation discusses using finasteride or dutasteride to reduce DHT, CosmeRNA to target androgenreceptors, and Minoxidil as a vasodilator for hair growth. The regimen aims to maintain hair by addressing DHT-AR ratio and continuous Minoxidil use.
To minimize hair loss while using steroids, use finasteride or dutasteride and apply topical anti-androgens like RU58841. Avoid high doses of hair-toxic steroids; prefer testosterone, nandrolone, and boldenone.
The conversation discusses GT20029, a drug in Phase II trials that targets androgenreceptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgenreceptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgenreceptors.
RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgenreceptor upregulation.
A user is experiencing continued hair loss despite using 0.5mg dutasteride and 2.5mg minoxidil, and is seeking advice on why the treatments aren't working and how to address potential androgenreceptor sensitivity. Replies suggest getting tested and considering scalp micropigmentation (SMP).
Hair loss is linked to scalp fibrosis and tension, which result from chronic mechanical stress and androgenic signaling. Treatments include blocking androgens with finasteride, promoting hair growth with topical minoxidil, and improving scalp mobility through exercises.
Some people have side effects from finasteride and dutasteride due to hormonal predisposition, especially if DHT dominant. Alternatives like RU58841, Pyrilutamide, and Breezula are suggested to target scalp androgenreceptors without altering overall hormones.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgenreceptor deleter, both requiring ongoing use for effectiveness.
He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgenreceptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgenreceptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgenreceptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgenreceptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgenreceptors in the scalp.
The conversation discusses whether creatine causes hair loss for those using finasteride or dutasteride, with some suggesting creatine might increase DHT or upregulate androgenreceptors, potentially leading to hair loss. Others argue the evidence is not conclusive, citing limited studies and personal anecdotes, with some avoiding creatine as a precaution.
The conversation discusses the link between seborrheic dermatitis, acne, and male pattern baldness, suggesting that DHT may cause both skin conditions and hair loss. Treatments mentioned include RU58841, finasteride, dutasteride, minoxidil, Nizoral shampoo, and other topical anti-androgens.
The user discusses their struggle with hair loss and inability to use Minoxidil or finasteride due to medical conditions. They are currently using Hairmetto gel and dermarolling, and are considering trying Breezula or Revivhair serum.
Combining Finasteride with topical Quercetin, Onion/Garlic juice and Peppermint Oil to reduce Wet Prostate Weight in Rats. Luke10191 asked the user LITUATUI to update them on progress after trying this combination of treatments for hair loss.
Topical spironolactone is discussed as a hair loss treatment, with concerns about its effectiveness and side effects compared to finasteride and minoxidil. Users mention its unpleasant smell, potential systemic absorption, and suggest alternatives like pyrilutamide and alfatradiol.
Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.
Topical sodium valproate may promote hair growth by inhibiting GSK3β, allowing beta-catenin to proliferate, but it has potential side effects and requires more research. The conversation also mentions skepticism about a product called Vdphlo1, which includes sodium valproate and other ingredients.
The conversation discusses the potential of using topical estrogen treatments for hair loss without systemic absorption, highlighting challenges and possible solutions like using estriol. It also mentions other treatments like topical finasteride, microneedling, and scalp massage, while noting the limitations and side effects of current options.
The user has been using 5% minoxidil once daily and microneedling with a 1.5 mm dermaroller weekly for three months, considering increasing minoxidil usage but avoiding finasteride due to libido concerns. Another person suggests considering other treatments like RU58841, alfatradiol, topical finasteride, clascoterone, or saw palmetto since not using a DHT blocker could be less effective.
Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.
The conversation discusses the use of topical minoxidil and finasteride for hair loss, with some users combining them with oral treatments. Users share their experiences and opinions on effectiveness, cost, and convenience, with mixed views on whether topical or oral applications are superior.
A user shared their successful hair loss treatment using RU58841, topical minoxidil, and microneedling, noting significant improvement over three months. They chose RU58841 over finasteride due to personal preference and reported no side effects, while others discussed their experiences with different treatments and supplements.
Topical dutasteride is considered for hair loss, but concerns about systemic absorption and side effects like reduced libido are common. Users have mixed results, with some preferring oral finasteride or dutasteride despite side effects, while others find topical treatments beneficial but challenging.